



DATE: May 30, 2002 SHEET 1 of 1

TECH CENTER 1600/2900

JUN 06 2002

RECEIVED

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6791.US.02

SERIAL NO.

10/081,207

APPLICANT(S)

M. Cowart *et al.*

FILING DATE

February 25, 2002

GROUP ART NO.

1642

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | INVENTOR | CLASS | SUB CLASS | FILING DATE |
|---------------------|----|---------------|---------------|------------------------|-------|--------------|----------------|
| VB | A1 | US 4,297,369 | 10/27/1981 | Takizawa <i>et al.</i> | 424 | 285 | 07/28/1980 |
| M | A2 | US 4,447,620 | 05/08/1984 | Sih <i>et al.</i> | 548 | 336 | 10/12/1982 |
| M | A3 | US 4,452,986 | 06/05/1984 | Johnson <i>et al.</i> | 548 | 336 | 09/30/1982 |
| M | A4 | US 5,648,372 | 07/15/1997 | Naito <i>et al.</i> | 514 | 383 | 02/01/1995 |
| M | | | | | | | |
| M | | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| | | DOCUMENT NUMBER | PUBLIC- ATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUB CLASS | TRANS- LATION | |
|---|----|-----------------|--------------------------|-----------------------------|-------|--------------|------------------|----|
| | | | | | | | YES | NO |
| M | B1 | 0 169 012 A1 | 22.01.1986 | EP | | | | |
| M | B2 | 94/26738 | 24.11.1994 | WO | | | | |
| M | B3 | 0 978 512 A1 | 09.02.2000 | EP | | | | |
| M | B4 | 00/06254 | 10.02.2000 | WO | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | | |
|---|----|--|
| M | C1 | LEURS, R., <i>et al.</i> "Therapeutic potential of histamine H ₃ receptor agonists and antagonists", Trends in Pharmacological Sciences 1998, Vol. 19 (5), pp. 177-183 (May 1998) |
| M | C2 | HAAS, H., <i>et al.</i> "Subcortical modulation of synaptic plasticity in the hippocampus", Behavioural Brain Research, Germany, Vol. 66, pp. 41-44 (Jan. 1995) |
| M | C3 | SCHWARTZ, J., <i>et al.</i> "Histaminergic transmission in the mammalian brain", Physiological Reviews, France, Vol. 71, No. 1, pp. 1-51 (Jan. 1991) |
| | | |
| | | |

EXAMINER

V. Balasubramanian

DATE CONSIDERED

6/24/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

#5

DATE March 19, 2003 SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6791.US.02

SERIAL NO.

10/081,207

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)


Coward, et al.

FILING DATE

February 22, 2002

MAR 26 2003

1624

RECEIVED
MAR 26 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | INVENTOR | CLASS | SUB CLASS | FILING DATE |
|---------------------|----|---------------|---------------|--------------------|-------|--------------|----------------|
| VB | A1 | 3,903,092 | 09/02/1975 | Chapman et al. | 260 | 293 | 10/24/1972 |
| IM | A2 | 3,910,955 | 10/07/1975 | Chapman et al. | 260 | 330 | 06/18/1973 |
| IM | A3 | 4,237,144 | 12/02/1980 | Cragoe et al. | 424 | 270 | 06/21/1979 |
| IM | A4 | 4,495,357 | 01/22/1985 | Johnson | 546 | 269 | 09/30/1982 |
| IM | A5 | 5,436,246 | 07/25/1995 | Bernotas et al. | 514 | 255 | 09/15/1993 |
| IM | A6 | 5,747,508 | 05/05/1998 | Richter et al. | 514 | 320 | 12/06/1996 |
| IM | A7 | 5,858,995 | 01/12/1999 | Kawai et al. | 514 | 100 | |
| IM | A8 | 6,302,837 | 10/16/1901 | De Nanteuil et al. | 574 | 337 | 10/13/2000 |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| | | DOCUMENT NUMBER | PUBLIC-ATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUB CLASS | TRANS- LATION YES NO |
|----|-----|--------------------|----------------------|-----------------------------|-------|--------------|----------------------------|
| IM | B1 | 0 512 570 | 11.10.1995 | EP | | | |
| IM | B2 | 0 982 300 | 01.03.2000 | EP | | | |
| IM | B3 | 01/23380 | 05.04.2001 | WO | | | |
| IM | B4 | 02/10156 | 07.02.2002 | WO | | | |
| IM | B5 | 95/04052 | 09.02.1995 | WO | | | |
| IM | B6 | 95/29907 | 09.11.1995 | WO | | | |
| IM | B7 | 96/11192 | 18.04.1996 | WO | | | |
| IM | B8 | 98/38188 | 03.09.1998 | WO | | | |
| IM | B9 | 98/52946 | 26.11.1998 | WO | | | |
| IM | B10 | 99/61435 | 02.12.1999 | WO | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | | | | | | | |
|----|----|---|--|--|--|--|--|
| IM | C1 | Descamps et al., "Benzofurans. XLII. Synthesis of 2-benzofurylmethylamines and amides of coumarilic acids," Chimica terapeutica 5(3):169-184 (1970) | | | | | |
| IM | C2 | JP 07173158 Abstracts | | | | | |

EXAMINER


V. Balasubraman

DATE CONSIDERED

6/24/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)



DATE: April 14, 2004

SHEET 1 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6791US02

SERIAL NO.

10/081,207

APPLICANT(S)

Cowart, et al.

FILING DATE

February 25, 2002

GROUP

1624

U.S. PATENT DOCUMENTS


| EXAMINER INITIAL | PATENT NUMBER | ISSUE DATE | INVENTOR | CLASS | SUB CLASS | FILING DATE |
|---------------------|---------------|---------------|----------|-------|--------------|----------------|
| | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION


| DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUB CLASS | TRANS- LATION YES NO |
|--------------------|---------------------|-----------------------------|-------|--------------|----------------------------|
| | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | | |
|---|-----|---|
| M | C1 | Bjenning et al., "Peripherally Administered Ciproxifan Elevates Hypothalamic Histamine Levels And Potently Reduces Food Intake in the Sprague Dawley Rat," Histamine Research In The New Millennium, Proceedings Of The International Sendai Histamine Symposium Held In Sendai, Japan, 22-25 November 2000, p. 449-450 |
| M | C2 | De Almeida et al., "Memory Facilitation by Histamine," Arch. Int. Pharmacodyn., 283:193-198 (1986). |
| M | C3 | Delaunois et al., "Modulation Of Acetylcholine, Capsaicin and Substance P Effects by Histamine H ₃ Receptors in Isolated Perfused Rabbit Lungs," European Journal Of Pharmacology, 277:243-250 (1995). |
| M | C4 | Dimitriadou et al., "Functional Relationship Between Mast Cells and C-Sensitive Nerve Fibres Evidenced by Histamine H ₃ -Receptor Modulation in Rat Lung and Spleen," Clinical Science, 87:151-163 (1994). |
| M | C5 | Duméry et al., "Development of Amygdaloid Cholinergic Mediation of Passive Avoidance Learning in the Rat," Exp. Brain. Res., 67:61-69 (1987). |
| M | C6 | Ellingboe et al., "Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole 2-Oxides," J. Med. Chem. 36:2485-2493 (1993) |
| M | C7 | Fitzsimons et al., "Histamine Receptors Signalling in Epidermal Tumor Cell Lines With H-ras Gene Alterations," Inflamm. Res., 47, Supplement 1, S50-S51 (1998). |
| M | C8 | Haas et al., Subcortical Modulation of Synaptic Plasticity in the Hippocampus," Behavioural Brain Research, 66:41-44 (1995). |
| M | C9 | Hatta et al., "Activation of Histamine H ₃ Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Prolonged Myocardial Ischemia ^{1,2} ," The Journal Of Pharmacology And Experimental Therapeutics, 283(2):494-500 (1997). |
| M | C10 | Imamura et al., "Activation Of Histamine H ₃ -Receptors Inhibits Carrier-Mediated Norepinephrine Release During Prolonged Myocardial Ischemia," Circulation Research, 78(3):475-481 (1996). |
| M | C21 | Imamura et al., "Histamine H ₃ -Receptor-Mediated Inhibition Of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers," Circulation Research, 78(5):863-869 (1996). |



| | | |
|---|-----|--|
| | C14 | Kamei et al., "Participation Of Histamine In The Step-Through Active Avoidance Response And Its Inhibition By H ₁ -Blockers," Japan J. Pharmacol., 57:473-482 (1991). |
| | C15 | Leurs et al., "The Histamine H ₃ -Receptor: A Target For Developing New Drugs," Progress In Drug Research, 39:127-165 (1992). |
| M | C16 | Leurs et al., "The Medicinal Chemistry And Therapeutic Potentials Of Ligands Of The Histamine H ₃ Receptor," Progress In Drug Research, 45:107-165 (1995). |
| M | C17 | Leurs et al., "Therapeutic Potential Of Histamine H ₃ Receptor Agonists And Antagonists," Trends In Pharm. Sci, 19:177-183 (1998). |
| M | C18 | Levi et al., "Histamine H ₃ -Receptors: A New Frontier In Myocardial Ischemia," The Journal Of Pharmacology And Experimental Therapeutics, 292(3):825-830 (2000). |
| M | C19 | Lin et al., "Involvement Of Histaminergic Neurons In Arousal Mechanisms Demonstrated With H ₃ -Receptor Ligands In The Cat," Brain Research, 523:325-330 (1990). |
| M | C20 | Matsubara et al., "UK-14,304, R(-) α -Methyl-Histamine And SMS 201-995 Block Plasma Protein Leakage Within Dura Mater By Prejunctional Mechanisms," European Journal Of Pharmacology, 224:145-150 (1992). |
| M | C21 | Mazurkiewicz-Kwilecki et al., "Changes In The Regional Brain Histamine And Histidine Levels In Postmortem Brains Of Alzheimer Patients," Can. J. Physiol. Pharmacol, 67: 75-78 (1989). |
| M | C22 | McLeod et al., "Histamine H ₃ Antagonists," Progress In Resp. Research 31:133-134 (2001) |
| M | C23 | Monti et al., "Effects Of Selective Activation Or Blockade Of The Histamine H ₃ Receptor On Sleep And Wakefulness," European Journal Of Pharmacology, 205:283-287 (1991). |
| M | C24 | Monti et al., "Sleep And Waking During Acute Histamine H ₃ Agonist BP2.94 Or H ₃ Antagonist Carboperamide (MR 16155) Administration In Rats," Neuropsychopharmacology, 15(1):31-35 (1996). |
| M | C25 | Murakami et al., "AQ-0145, A Newly Developed Histamine H ₃ Antagonist, Decreased Seizure Susceptibility Of Electrically Induced Convulsions In Mice," Meth. Find. Exp. Clin. Pharmacol. 17(C):70-73 (1995) |
| M | C26 | Onodera et al., "Neuropharmacology Of The Histaminergic Neuron System In The Brain And Its Relationship With Behavioral Disorders," Progress In Neurobiology, 42:685-702 (1994). |
| M | C27 | Panula et al., "Histamine Neurons in Human Hypothalamus: Anatomy in Normal and Alzheimer Diseased Brains," Neuroscience 44(2):465-481 (1991) |
| M | C28 | Panula et al., "Neuronal Histamine Deficit in Alzheimer's Disease," Neuroscience 82(4):993-997 (1998) |
| M | C29 | Perez-Garcia et al., "Effects Of Histamine H ₃ Receptor Ligands In Experimental Models Of Anxiety And Depression," Psychopharmacology 142:215-220 (1999) |
| M | C30 | Phillips et al., "Recent Advances In Histamine H ₃ Receptor Agents," Annual Reports In Medicinal Chemistry, 33:31-40 (1998). |
| M | C31 | Rouleau, "Bioavailability, Antinociceptive And Antiinflammatory Properties Of BP 2-94, A Histamine H ₃ Receptor Agonist Prodrug," The Journal Of Pharmacology And Experimental Therapeutics, 281(3):1085-1094 (1997). |
| M | C32 | Sakai et al., "Effects Of Thioperamide, A Histamine H ₃ Receptor Antagonist, On Locomotor Activity And Brain Histamine Content In Mast Cell-Deficient W/W ^v Mice," Life Sciences, 48:2397-2404 (1991). |
| M | C33 | Schwartz et al., "Histaminergic Transmission in the Mammalian Brain," Physiological Reviews 71(1):1-51 (1991) |
| M | C34 | Schwartz et al., "Histamine," Psychopharmacology: The Fourth Generation Of Progress, 397-405 (1995). |
| M | C35 | Shaywitz et al., "Dopaminergic But Not Noradrenergic Mediation Of Hyperactivity And Performance Deficits In The Developing Rat Pup," Psychopharmacology, 82:73-77 (1984). |
| M | C36 | Szelag, "Role Of Histamine H ₃ -Receptors In The Proliferation Of Neoplastic Cells In Vitro," Med. Sci. Monit., 4(5):747-755 (1998). |
| M | C37 | Tedford et al., "Cognition And Locomotor Activity In The Developing Rat: Comparisons Of Histamine H ₃ Receptor Antagonists And ADHD Therapeutics," Society For Neuroscience Abstr., 22:22 (1996). |
| M | C38 | Tedford et al., "Pharmacological Characterization Of GT-2016, A Non-Thiourea-Containing Histamine H ₃ Receptor Antagonist: <i>In Vitro</i> And <i>In Vivo</i> Studies," The Journal Of Pharmacology And Experimental Therapeutics, 275(2):598-604 (1995). |
| M | C39 | Wada et al., "Is The Histaminergic Neuron System A Regulatory Center For Whole-Brain Activity?," Trends In Neurosciences, 14(9):415-418 (1991). |



| | |
|-----|--|
| C40 | Yates et al., "Effects Of A Novel Histamine H ₃ Receptor Antagonist, GT-2394, On Food Intake And Weight Gain In Sprague-Dawley Rats," Abstracts, Society For Neuroscience, 102.10:219 (November 2000) |
| C41 | Yokoyama et al., "Effect Of Thioperamide, A Histamine H ₃ Receptor Antagonist, On Electrically Induced Convulsions In Mice," Journal Of Pharmacology, 234:129-133 (1993). |
| C42 | Yokoyama et al., "Histamine And Seizures Implications For The Treatment Of Epilepsy," CNS Drugs, 5(5):321-330 (1996). |

EXAMINER

V. Balasubraman

DATE CONSIDERED

6/24/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)